Home
Resources
Follow portfolio news
...

Idoven joins forces with AstraZeneca to improve early diagnosis of cardiovascular disorders

Published on
7/12/2022
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
Idoven logo
In an innovative project, Idoven and AstraZeneca are working together to improve early diagnosis of cardiovascular disease using artificial intelligence. The aim of this partnership is to identify patients at risk of heart failure in a matter of minutes, thereby facilitating appropriate remote monitoring. A major step forward in the fight against these diseases.
By
Damien Hélène
Damien Hélène
Idoven joins forces with AstraZeneca to improve early diagnosis of cardiovascular disorders
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

As part of a pioneering project in Europe, Idoven, a company specializing in the detection of cardiovascular disease using artificial intelligence, has announced a strategic collaboration with AstraZeneca to improve the early diagnosis of cardiovascular disorders, particularly heart failure (characterized by a reduction in the heart's ability to pump blood efficiently).

One of the most widespread pathologies, and the leading cause of death worldwide, cardiovascular disease often goes unrecognized and undiagnosed due to the absence of specific symptoms in the early stages of the disease.

The project led by AstraZeneca and Idoven aims to use artificial intelligence to optimize and accelerate diagnosis and follow-up of heart failure patients over 65.

" Our artificial intelligence-based platform will be able to identify patients at high risk of heart failure within minutes, with the results reviewed and confirmed by our team of cardiologists before being shared with the attending physician for further follow-up," explains Manuel Marina, cardiologist and CEO of Idoven. Patients will then be monitored remotely, using devices that create and record an electrocardiogram from the wrist. In collaboration with Idoven, this information will be shared with healthcare professionals.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Europe
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.